Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.52 |
| ▸ | AKT2 | P31751 | 14/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 14/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455063 | 0.94 | AKT1 (0.51) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455079 | 0.92 | AKT1 (0.49) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455271 | 0.89 | AKT1 (0.59) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455420 | 0.87 | AKT1 (0.51) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455456 | 0.86 | AKT1 (0.54) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455156 | 0.86 | AKT1 (0.54) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455396 | 0.86 | AKT1 (0.59) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455295 | 0.85 | AKT1 (0.60) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455159 | 0.84 | AKT1 (0.53) | AKT1AKT2AKT3CYP2C9CYP1A2 | |
| SCHEMBL31455309 | 0.82 | AKT1 (0.68) | AKT1AKT2AKT3CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |